)
)
Alligator Bioscience Investor Relations Material
Latest events
Q3 2024
Alligator Bioscience
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Alligator Bioscience
Access all reports
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Latest articles
)
House of Warhammer: The Inner Workings of Games Workshop
A look under the hood of Games Workshop, a high-margin business in an incredibly niche market, with sky-high stock returns.
15 Nov 2024
)
Crafting a Solid Equity Story: A Strategic Guide for Investor Relations Professionals
Craft a compelling equity story: Align narratives with data to attract ideal investors and build trust with Quartr Pro's powerful IR tools.
13 Nov 2024
)
Our List of 100 Eminent Serial Acquirers
Serial acquirers have deep experience in mastering value creation through reallocating resources across their portfolio of acquired companies.
12 Nov 2024
Ticker symbol
ATORX
Country
🇸🇪 Sweden